The Myelodysplastic Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Myelodysplastic Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Myelodysplastic Syndrome and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Myelodysplastic Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Latest Development in the Myelodysplastic Syndrome Therapeutics Market
On April 26, 2023, Geron Corporation (Nasdaq: GERN) announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company’s first-in-class telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes (MDS), was accepted for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The data in the ASCO abstract will be embargoed per ASCO guidelines until May 25, 2023, at 5 p.m. Eastern Time. ASCO is taking place in Chicago, IL, from June 2-6, 2023.
Learn How the Ongoing Clinical & Commercial Activities will Affect the Myelodysplastic Syndrome Therapeutic Segment @
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight
The Leading Companies in the Myelodysplastic Syndrome Therapeutics Market Include:
AbbVie
Antengene Corporation
Aprea Therapeutics
Astex Pharmaceutical
BerGenBio ASA
Bristol-Myers Squibb
Fibrogen
Geron Corporation
Gilead Sciences
Jazz Pharmaceuticals
Karyopharm Therapeutics
Medac
Novartis
Pfizer
Sanofi
Syros Pharmaceuticals
Taiho Oncology
Takeda
And Many Others
Myelodysplastic Syndrome Emerging Drugs
Bemcentinib: BerGenBio
CPX-351: Jazz Pharmaceuticals
Eltanexor: Karyopharm Therapeutics
Enasidenib: Bristol Myers Squibb
Eprenetapopt: Aprea Therapeutics
Fludarabine + busulfan ± clofarabine: Sanofi
Glasdegib + Azacitidine: Pfizer
Imetelstat: Geron Corporation
Inqovi: Astex Pharmaceutical/Taiho Oncology
Magrolimab ± Azacitidine: Gilead Sciences
Pevonedistat ± Azacitidine: Takeda
Reblozyl: Bristol-Meyers Squibb
Roxadustat: FibroGen
Sabatolimab: Novartis
SY-1425 + azacitidine: Syros Pharmaceuticals
Treosulfan ± fludarabine: Medac
Venclexta ± azacitidine: AbbVie
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Myelodysplastic Syndrome Current Treatment Patterns
4. Myelodysplastic Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Myelodysplastic Syndrome Late Stage Products (Phase-III)
7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)
8. Myelodysplastic Syndrome Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myelodysplastic Syndrome Discontinued Products
13. Myelodysplastic Syndrome Product Profiles
14. Key Companies in the Myelodysplastic Syndrome Market
15. Key Products in the Myelodysplastic Syndrome Therapeutics Segment
16. Dormant and Discontinued Products
17. Myelodysplastic Syndrome Unmet Needs
18. Myelodysplastic Syndrome Future Perspectives
19. Myelodysplastic Syndrome Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
